Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.

Saved in:
Bibliographic Details
Title: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
Authors: Fay JW; Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, TX 75204, USA. josephf@baylorhealth.edu, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, Ueno H, Banchereau J
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2006 Oct; Vol. 55 (10), pp. 1209-18. Date of Electronic Publication: 2005 Dec 06.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0340-7004 (Print) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:0340-7004
DOI:10.1007/s00262-005-0106-6